Form 4: Moderna CFO Reports Stock Transactions

Moderna's Chief Financial Officer, James M. Mock, has reported transactions involving restricted stock units and common stock.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc., reported transactions on July 2, 2026.
• He acquired 1,452 shares of common stock through the conversion of restricted stock units (RSUs).
• Following this acquisition, Mock beneficially owns 67,139 shares of common stock.
• Additionally, 703 shares were disposed of for a price of $72.50 each, related to tax withholding obligations upon the vesting of RSUs.
• After these disposals, Mock beneficially owns 66,436 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine stock transactions related to executive compensation and tax obligations, without indicating significant buying or selling pressure.

Positives

• The conversion of RSUs into common stock indicates the fulfillment of equity-based compensation, aligning management's interests with shareholders.
• The acquisition of 1,452 shares by the CFO demonstrates continued ownership in the company.

Negatives

• The disposal of 703 shares to cover tax withholding obligations, while standard, represents a reduction in the CFO's direct holdings.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders, providing transparency into their stock transactions. These filings are crucial for investors seeking to understand insider sentiment and potential shifts in beneficial ownership.

Stakeholder Impact

• Shareholders: Gain insight into the CFO's direct holdings and transactions, which can inform their perception of insider confidence.
• Employees: The vesting and conversion of RSUs highlight the company's equity compensation structure.
• Regulatory Bodies: Compliance with SEC disclosure requirements is maintained.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Common Stock, Beneficial Ownership, Chief Financial Officer, James M. Mock